CASI Enters $95 Million China Deal for BioInvent's Checkpoint Inhibitor

CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden 's BioInvent in a $95 million deal. BI-1206 is a FcγRIIB inhibitor that is being tested as a treatment for hematological and solid tumors. BioInvent is conducting a Phase I/II trial of BI-1206 in combination with PD-1 therapy Keytruda in solid tumors, and with MabThera in non-Hodgkin lymphoma. CASI will be in charge of BI-1206 commercialization in greater China . Headquartered in Maryland , CASI markets oncology drugs in China . More details.... Stock Symbols: (NSDQ: CASI) (OMXS: BINV) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.